Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Soluble programmed death-ligand 1 rather than PD-L1 on tumor cells effectively predicts metastasis and prognosis in soft tissue sarcomas
Kunihiro Asanuma, Tomoki Nakamura, Akinobu Hayashi, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 48

Showing 1-25 of 48 citing articles:

Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis
Yibo Fan, Xiaofang Che, Jinglei Qu, et al.
Annals of Surgical Oncology (2019) Vol. 26, Iss. 11, pp. 3745-3755
Closed Access | Times Cited: 159
Biological Characteristics and Clinical Significance of Soluble PD-1/PD-L1 and Exosomal PD-L1 in Cancer
Mengke Niu, Yiming Liu, Ming Yi, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 92
Soluble Programmed Death Ligand-1 (sPD-L1): A Pool of Circulating Proteins Implicated in Health and Diseases
Christian Bailly, Xavier Thuru, Bruno Quesnel
Cancers (2021) Vol. 13, Iss. 12, pp. 3034-3034
Open Access | Times Cited: 97
Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment
So Yeon Oh, Soyeon Kim, Bhumsuk Keam, et al.
Scientific Reports (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 92
Exosomal PD-L1: New Insights Into Tumor Immune Escape Mechanisms and Therapeutic Strategies
Kaijian Zhou, Shu Guo, Fei Li, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 76
Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review
Matthieu Roulleaux Dugage, Elise F. Nassif, Antoîne Italiano, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 60
Soluble immune checkpoints: implications for cancer prognosis and response to immune checkpoint therapy and conventional therapies
Stephanie Pitts, Jeffrey Schlom, Renee N. Donahue
Journal of Experimental & Clinical Cancer Research (2024) Vol. 43, Iss. 1
Open Access | Times Cited: 8
Nivolumab plus ipilimumab, with or without enzalutamide, in AR‐V7‐expressing metastatic castration‐resistant prostate cancer: A phase‐2 nonrandomized clinical trial
Eugene Shenderov, Karim Boudadi, Wei Fu, et al.
The Prostate (2021) Vol. 81, Iss. 6, pp. 326-338
Open Access | Times Cited: 55
Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients
Mihaela Chivu‐Economescu, Vlad Herlea, Simona Dima, et al.
Gastric Cancer (2023) Vol. 26, Iss. 6, pp. 934-946
Closed Access | Times Cited: 15
Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?
Daniele Fanale, Lorena Incorvaia, Giuseppe Badalamenti, et al.
Cancers (2021) Vol. 13, Iss. 9, pp. 2118-2118
Open Access | Times Cited: 28
Prognostic significance of soluble PD-L1 in prostate cancer
Margarita Zvirble, Žilvinas Survila, Paulius Bosas, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Soluble immune checkpoint molecules in cancer risk, outcomes prediction, and therapeutic applications
Lin Chen, Yuqing Chao, Wenjing Li, et al.
Biomarker Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 4
Soluble immune checkpoint molecules: mechanism of formation, function, role in malignant neoplasms
Glazanova Tv, Irina Pavlovа, E. V. Kuzmich, et al.
Medical Immunology (Russia) (2025) Vol. 27, Iss. 1, pp. 21-34
Open Access
Soluble PD-L1: From Immune Evasion to Cancer Therapy
Laura Denisa Dragu, Laura Georgiana Necula, Coralia Bleoţu, et al.
Life (2025) Vol. 15, Iss. 4, pp. 626-626
Open Access
Clinical and Prognostic Value of Antigen-Presenting Cells with PD-L1/PD-L2 Expression in Ovarian Cancer Patients
Anna Pawłowska, Agnieszka Kwiatkowska, Dorota Suszczyk, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 21, pp. 11563-11563
Open Access | Times Cited: 25
Integrating Molecular Biomarker Inputs Into Development and Use of Clinical Cancer Therapeutics
Anna D. Louie, Kelsey E. Huntington, Lindsey Carlsen, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 24
Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches
Ji Eun Won, Youngseon Byeon, Tae In Wi, et al.
Journal for ImmunoTherapy of Cancer (2022) Vol. 10, Iss. 2, pp. e003928-e003928
Open Access | Times Cited: 17
Soluble PD-L1 as a Predictive Biomarker in Lung Cancer: A Systematic Review and Meta-Analysis
Yang Cheng, Chong Wang, Yan Wang, et al.
Future Oncology (2021) Vol. 18, Iss. 2, pp. 261-273
Closed Access | Times Cited: 23
Prognostic Role of Soluble Programmed Death Ligand 1 in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Guixiang Liao, Zhihong Zhao, Yuting Qian, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 21
Brain Cancer Drug Discovery: Clinical Trials, Drug Classes, Targets, and Combinatorial Therapies
Aleksandr V. Sokolov, Samira A. Dostdar, Misty M. Attwood, et al.
Pharmacological Reviews (2021) Vol. 73, Iss. 4, pp. 1172-1203
Open Access | Times Cited: 18
Epstein–Barr Virus LMP1 Induces Soluble PD-L1 in Nasopharyngeal Carcinoma
Kina Kase, Satoru Kondo, Naohiro Wakisaka, et al.
Microorganisms (2021) Vol. 9, Iss. 3, pp. 603-603
Open Access | Times Cited: 16
Immune checkpoint expression on peripheral cytotoxic lymphocytes in cervical cancer patients: moving beyond the PD-1/PD-L1 axis
Fabiola Solorzano‐Ibarra, Alan Guillermo Alejandre‐Gonzalez, Pablo César Ortiz-Lazareno, et al.
Clinical & Experimental Immunology (2020) Vol. 204, Iss. 1, pp. 78-95
Open Access | Times Cited: 16
Soluble Levels of CD163, PD-L1, and IL-10 in Renal Cell Carcinoma Patients
Sabina Davidsson, Sofia Huotilainen, Jessica Carlsson, et al.
Diagnostics (2022) Vol. 12, Iss. 2, pp. 336-336
Open Access | Times Cited: 10
The Prognostic Value of Circulating Soluble Programmed Death Ligand-1 in Cancers: A Meta-Analysis
Pei Huang, Wei Hu, Ying Zhu, et al.
Frontiers in Oncology (2021) Vol. 10
Open Access | Times Cited: 14
Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
Yijun Jia, Xuefei Li, Chao Zhao, et al.
Frontiers in Oncology (2020) Vol. 10
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top